格隆汇10月14日丨恒瑞医药(01276.HK)发布公告，2025年10月14日耗资人民币1306.63万元回购20万股A 股，回购价格每股64-67元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年10月14日斥资1306.63万元人民币回购20 万股A股，每股回购价格为64-67元人民币。 ...

大和发布研报称，首次覆盖恒瑞医药（600276）(01276)H股予"持有"评级，目标价86港元。该行指，恒 瑞医药的创新药授权在行业中较为领先，因集团拥有商业化的创新药组合，研发管线中有超过90种新分 子实体，并正在发展业务拓展(BD);该行预期2025至27年的授权收入分别达41亿、29亿及10亿元人民 币。该行看好其基本面，催化剂包括国内的创新药销售增长、药物数据释出、BD交易及获授权项目的 海外进展。 ...

智通财经APP获悉，大和发布研报称，首次覆盖恒瑞医药(01276)H股予"持有"评级，目标价86港元。该 行指，恒瑞医药的创新药授权在行业中较为领先，因集团拥有商业化的创新药组合，研发管线中有超过 90种新分子实体，并正在发展业务拓展(BD);该行预期2025至27年的授权收入分别达41亿、29亿及10亿 元人民币。该行看好其基本面，催化剂包括国内的创新药销售增长、药物数据释出、BD交易及获授权 项目的海外进展。 ...

格隆汇10月14日｜大和发表报告，首次覆盖恒瑞医药H股，予"持有"评级，目标价86港元。该行指，恒 瑞医药的创新药授权在行业中较为领先，因集团拥有商业化的创新药组合，研发管线中有超过90种新分 子实体，并正在发展业务拓展(BD)。该行看好其基本面，催化剂包括国内的创新药销售增长、药物数 据释出、BD交易及获授权项目的海外进展。 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received clinical trial approval for two drugs, SHR-A2102 and SHR-1905, from the National Medical Products Administration, indicating progress in its drug development pipeline [1][6]. Group 1: Drug Information - SHR-A2102 is a targeted antibody-drug conjugate (ADC) that targets Nectin-4, with a payload of topoisomerase I inhibitor (TOP1i). It is undergoing a Phase II clinical trial for safety, tolerability, and efficacy in advanced solid tumors [1][2]. - SHR-1905 is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), aimed at treating atopic dermatitis. It has also received approval for clinical trials [6][7]. Group 2: Market Context - The global sales of a similar product to SHR-A2102, Enfortumab vedotin (brand name: Padcev), are projected to be approximately $1.949 billion in 2024 [2]. - The global sales of a comparable product to SHR-1905, Tezepelumab (brand name: Tezspire), are estimated to be around $1.22 billion in 2024 [7]. Group 3: R&D Investment - The cumulative R&D investment for SHR-A2102 is approximately 224.84 million yuan [2]. - The cumulative R&D investment for SHR-1905 is about 209.62 million yuan [7]. - The cumulative R&D investment for SHR-1802, another drug in development, is around 62.09 million yuan [12]. - The cumulative R&D investment for the anti-PD-L1 monoclonal antibody, Abedilizumab, is approximately 939.08 million yuan [13].

Group 1 - Jiangsu Province Sports Bureau announced that the "Su Super" league will continue to be held in 2026, with optimized player selection rules to enhance the league's connection to youth training [1] - The 2025 Nobel Prize in Economic Sciences was awarded to Joel Mokyr, Philippe Aghion, and Peter Howitt for their contributions to understanding innovation-driven economic growth [2] - eBay's CEO Jamie Iannone stated that the platform was "overconfident" in 2020 and is now focusing on core users, predicting a 50% stock increase by 2025 [2] Group 2 - Google expressed concerns that Australia's new law restricting social media use for those under 16 will be "extremely difficult to enforce" and may not achieve its goal of improving children's online safety [3] - Heng Rui Medicine announced that three drugs received clinical trial approval from the National Medical Products Administration, with significant R&D investments of approximately 225 million yuan, 62.09 million yuan, and 939 million yuan for the respective drugs [4][5] - Domestic gasoline and diesel prices will be reduced by 70 yuan and 75 yuan per ton respectively, effective from October 13, with a decrease of 0.06 yuan per liter for 92 and 95 gasoline [6] Group 3 - Inner Mongolia First Machinery Group issued a statement regarding unauthorized use of its name in a WeChat group, emphasizing that it has not registered or authorized any such services [7] - China Southern Airlines will launch direct flights from Guangzhou to Madrid and Darwin in December 2025, with specific flight schedules provided [8] - Meituan announced a "full refund for side effects" policy for certain medications, allowing users to return drugs if side effects occur within 21 days [9] Group 4 - Tianzhen Co. stated that the impact of tariffs on its operations is relatively small, as the company has established a global production layout in Southeast Asia and the United States [10] - Xiaomi responded to concerns regarding the safety of its SU7 vehicle after a fatal accident, stating that the vehicle's doors will unlock upon collision [11]

Core Insights - The pharmaceutical index increased by 0.36% from September 29 to October 10, underperforming the CSI 300 index by -1.11% [1] - The "Most-Favored-Nation Pricing" agreement catalyzed significant stock price increases for U.S. MNCs, which also positively impacted Hong Kong's innovative drug sector, although there was a notable decline in the following trading days [1] - Anticipated catalysts in October include ESMO, BD, and medical insurance negotiations, which may stabilize and rebound innovative drug stocks [1] Market Performance - From September 29 to October 10, 316 stocks rose while 148 fell, with notable gainers including Zhendong Medical (+31.82%) and Wanbangde (+21.21%), while major losers included Nanxin Pharmaceutical (-28.67%) and ST Fuhua (-13.64%) [2] - Q3 performance expectations indicate a significant trend in innovative drug volume, with traditional pharmaceutical companies like Heng Rui expected to maintain Q2 trends [2] - Blood products and vaccines are projected to face continued pressure, while CXO and upstream research are expected to show good external demand growth [2] Investment Opportunities - The Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, with companies like Heng Rui and Han Sen making significant strides [3][4] - The demand for chronic disease treatments is increasing due to an aging population, supported by a stable growth in medical insurance revenue [4] - The AI wave is anticipated to unlock new growth logic in the pharmaceutical sector [4] Recommended Stocks - Current recommendations include Xintai, Rejing Bio, and China National Pharmaceutical, with a focus on companies like Heng Rui and Sanofi for October [5]

Investment Rating - The report suggests a positive outlook for the oligonucleotide drug industry, indicating that it is on the verge of a therapeutic paradigm revolution, particularly in the treatment of common diseases [3]. Core Insights - The oligonucleotide drug market is approaching a critical point of explosion, with significant advancements in delivery technologies and therapeutic targets [3]. - The report highlights the potential for multiple innovative treatment paradigms for common liver diseases over the next five years, focusing on lipid-lowering, blood pressure reduction, and hepatitis B [3]. - The report emphasizes the importance of differentiated delivery technologies and the potential for business development (BD) opportunities in the industry [3]. Summary by Sections Industry Overview - The report revisits the previous assessment from January 2021, which predicted that oligonucleotide drugs would become the third major class of therapeutics after small molecules and monoclonal antibodies [3]. - It notes that the market has seen a significant increase in the number of approved siRNA/ASO drugs since 2022, addressing unmet medical needs [4]. Market Dynamics - The report identifies key players in the industry, including Alnylam, Arrowhead, and Ionis, and discusses their market capitalization changes from 2021 to 2025, highlighting Alnylam's significant growth due to successful drug launches [7]. - It mentions that the market for oligonucleotide drugs is expanding into common diseases, with Alnylam's drugs like Amvuttra and Inclisiran showing strong sales potential [20]. Technological Advancements - The report discusses advancements in delivery technologies, particularly the GalNAc conjugation platform, which has significantly improved the efficacy and safety of oligonucleotide drugs [41][42]. - It highlights the ongoing research into dual-target oligonucleotide drugs, which may become a new trend in the industry [36]. Competitive Landscape - The report outlines the competitive landscape, noting that multinational corporations (MNCs) are actively acquiring clinical-stage FIC drugs and exploring collaborations with biotech firms [3]. - It emphasizes the need for targeted delivery systems for different organs, indicating that the advancement and differentiation of delivery platforms will be crucial for the future success of oligonucleotide drug companies [26][27].

Core Insights - The pharmaceutical companies listed on the Shanghai Stock Exchange have shown robust growth in the first half of 2025, driven by the implementation of the Healthy China strategy and global pharmaceutical innovation [1][4] - Jiangsu Hengrui Medicine Co., Ltd. has received approval for its innovative drug, Zemeituzhita Tablets, marking a significant advancement in China's hematological oncology drug development [1][2] - The overall trend indicates a shift towards increased R&D investment, with innovative drug sales becoming a larger portion of revenue and accelerated international market expansion [1][4] Company Summaries - **Hengrui Medicine**: Achieved revenue of 15.761 billion yuan and net profit of 4.450 billion yuan in the first half of 2025, representing year-on-year growth of 15.88% and 29.67% respectively. Innovative drug sales now account for 55% of main business revenue. The company has invested over 48 billion yuan in R&D and has 14 global R&D centers with a team of over 5,600 [2][3] - **Fosun Pharma**: Reported innovative drug revenue exceeding 4.3 billion yuan in the first half of 2025, a year-on-year increase of 14.26%, making up 31% of its pharmaceutical business revenue. The company has engaged in five innovative drug licensing transactions and has established a local team in the U.S. for commercialization efforts [2][3] - **WuXi AppTec**: Experienced a 24.2% year-on-year growth in revenue from continuing operations in the first half of 2025, with adjusted net profit increasing by 44.4%. The company has successfully synthesized and delivered over 440,000 new compounds in the past 12 months [3] Industry Trends - The pharmaceutical industry is actively exploring new growth points through digital transformation, green low-carbon development, and cross-industry innovation. Leading companies like Hengrui, Fosun, and WuXi AppTec are demonstrating the effectiveness of innovation-driven strategies and global market expansion [4]